Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Bacterial Infections Clinical Trials

A listing of Bacterial Infections medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (12) clinical trials

This is a study to assess the pharmacokinetics (PK) of tedizolid phosphate and its active metabolite, tedizolid, and the safety of tedizolid phosphate following administration of a single IV (Part A) or oral suspension (Part B) administration to hospitalized participants ages 6 to less than 12 years (Groups 1 and ...

Phase

The goal of this study is to compare changes in the female genital tract in women diagnosed with bacterial vaginosis (BV) before and after treatment and to compare differences in the female genital tract in adolescent and adult women. Women with BV have an increased risk of acquiring HIV and ...

Phase

Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics

The primary objective is to characterize the pharmacokinetics of single doses of ceftobiprole in neonates and infants aged 3 months. The secondary objective is to evaluate safety and tolerability of ceftobiprole in neonates and infants aged 3 months.

Phase

Open-Label Dose-Finding Pharmacokinetics Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections

This is a Phase 1, multicenter, open-label, PK, safety and tolerability study of oritavancin in pediatric patients (<18 years of age) with suspected or confirmed Gram-positive bacterial infections. Approximately 48 patients will be enrolled at 10-15 US centers. This study will include 5 age cohorts and patients will be entered ...

Phase

Dose-finding Pharmacokinetics Safety and Tolerability of Meropenem-Vaborbactam in Pediatric Subjects With Serious Bacterial Infections

In the current era of increased resistance to extended spectrum cephalosporins, carbapenem antimicrobial agents are frequently the antibiotics of "last defense" for the most resistant pathogens in serious infections, including those found in complicated Urinary Tract Infections (cUTI). The recent dissemination of serine carbapenemases (e.g. KPC) in Enterobacteriaceae in many ...

Phase

Study Evaluate the PK Profile of Dalbavancin in Hospitalized Infants and Neonates Patients With Known or Suspected Bacterial Infection

The purpose of this study is to evaluate the Pharmacokinetic (PK) profile of a single intravenous (IV) infusion dose of dalbavancin, and to evaluate the safety and tolerability of a single dalbavancin IV infusion.

Phase

A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants Ages 2 to <12 Years With Confirmed or Suspected Bacterial Infection (MK-1986-013)

Part A (IV): Group 1 (Cohort 1 and Cohort 2) (6 to <12 years) Group 2 (Cohort 1 and Cohort 2) (2 to <6 years) Part B (Oral Suspension): Group 3 (6 to <12 years) Group 4 (2 to <6 years) In Cohort 1 of Group 1 (IV) participants received ...

Phase

To Assess Bioavailability Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I Single-Dose 2 Part Study in Healthy Subjects.

This study is divided in 2 parts. Part 1a is being conducted to evaluate the safety, tolerability, and relative bioavailability of the 2 free base tablet formulations (related compound [RC] and high shear wet granulation [HSWG]) compared to the reference capsule formulation under fasted conditions. This is a 3-period; cross-over ...

Phase

A Phase 1 Safety and PK Study of IV TP-271

Up to 5 cohorts of 8 subjects each (up to a total of 40 subjects) will be enrolled. The 8 subjects within each cohort will be randomized 6:2 to receive multiple IV doses of TP-271 or placebo. Study drug will be administered IV once daily on the morning of Days ...

Phase

PK of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children

This is a PK and safety study in infants and children requiring prophylaxis of, or treatment for confirmed or suspected infection with clindamycin or TMP-SMX. Each subject will be involved in the study for up to 33 days (3 days of therapy, 30 days for serious adverse event monitoring). STUDY ...

Phase